Confocal.nl secures €5 Million investment to expand groundbreaking live cell microscopy
Amsterdam, October 17, 2024 – The Amsterdam-based technology company Confocal.nl has received a €5 million investment from a consortium of investors, including ROM InWest and Nascent Ventures. This funding will enable the company to make its innovative microscopes for live research more widely accessible worldwide. The technology helps scientists achieve breakthroughs more quickly, for example, in the development of more effective medicines or innovative agricultural crops.
Confocal.nl: ‘Live cell imaging for everyone’
Confocal.nl develops and produces advanced microscopes that allow scientists to study living cells in an unprecedented way—also known as “Live Cell Imaging.” Pim Vos, CEO of Confocal.nl, explains: “We are on the brink of major breakthroughs in the medical field, increasing the demand for experts who can work with confocal microscopy. Our technology can make a significant difference by making this complex technology more suitable and accessible for a broader group of scientists.”
What makes Confocal.nl unique is its use of minimal laser light at an extremely high resolution, allowing for longer and more reliable observation of living cells. Vos adds: “Traditional microscopes use intense laser light, which causes cells to behave differently, fade, or die more quickly. As a result, living cells can only be studied for a limited time. Our technology prevents this, enabling scientists to observe processes in living cells for longer and with greater precision, leading to more reproducible results. This is crucial for research into new drugs and treatments for complex diseases.”
New Investments for Further Growth
With this investment, Confocal.nl aims not only to further automate its products but also to increase its international brand recognition. “We are making our technology more accessible to both the scientific and industrial research communities. Additionally, we are investing in marketing and sales, particularly in Europe and the United States,” says Vos.